WO2003091700A3 - Epitope mapping using nuclear magnetic resonance - Google Patents

Epitope mapping using nuclear magnetic resonance Download PDF

Info

Publication number
WO2003091700A3
WO2003091700A3 PCT/US2003/009132 US0309132W WO03091700A3 WO 2003091700 A3 WO2003091700 A3 WO 2003091700A3 US 0309132 W US0309132 W US 0309132W WO 03091700 A3 WO03091700 A3 WO 03091700A3
Authority
WO
WIPO (PCT)
Prior art keywords
magnetic resonance
nuclear magnetic
epitope mapping
conformation
antigen
Prior art date
Application number
PCT/US2003/009132
Other languages
French (fr)
Other versions
WO2003091700A2 (en
Inventor
George A Heavner
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Priority to AU2003253589A priority Critical patent/AU2003253589A1/en
Publication of WO2003091700A2 publication Critical patent/WO2003091700A2/en
Publication of WO2003091700A3 publication Critical patent/WO2003091700A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Abstract

This invention relates to methods for mapping or otherwise identifying the amino acid sequence and conformation of a portion of a protein that is involved in ligand binding. This invention finds utility in the process of elucidating the amino acid sequence and conformation of an epitope of, for example, an antigen or an antibody that binds to the antigen.
PCT/US2003/009132 2002-03-26 2003-03-24 Epitope mapping using nuclear magnetic resonance WO2003091700A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003253589A AU2003253589A1 (en) 2002-03-26 2003-03-24 Epitope mapping using nuclear magnetic resonance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36789702P 2002-03-26 2002-03-26
US60/367,897 2002-03-26

Publications (2)

Publication Number Publication Date
WO2003091700A2 WO2003091700A2 (en) 2003-11-06
WO2003091700A3 true WO2003091700A3 (en) 2005-09-01

Family

ID=29270481

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009132 WO2003091700A2 (en) 2002-03-26 2003-03-24 Epitope mapping using nuclear magnetic resonance

Country Status (2)

Country Link
AU (1) AU2003253589A1 (en)
WO (1) WO2003091700A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
EP2635304B1 (en) * 2010-11-05 2017-03-08 Morphotek, Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
WO2022238350A1 (en) 2021-05-11 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Dnp biosensor

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698401A (en) * 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
US5958683A (en) * 1994-03-30 1999-09-28 Novartis Corporation Screening method using the RZR receptor family
US5977772A (en) * 1996-11-15 1999-11-02 Research Foundation Of State University Of New York, The Apparatus and method for high pressure NMR spectroscopy
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6333149B1 (en) * 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US20020004489A1 (en) * 1999-08-16 2002-01-10 Yanggu Shi Retinoid receptor interacting polynucleotides, polypeptides, and antibodies
US20020006640A1 (en) * 1999-11-04 2002-01-17 Jian Ni Uteroglobin-like polynucleotides, polypeptides, and antibodies

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5958683A (en) * 1994-03-30 1999-09-28 Novartis Corporation Screening method using the RZR receptor family
US5698401A (en) * 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
US5977772A (en) * 1996-11-15 1999-11-02 Research Foundation Of State University Of New York, The Apparatus and method for high pressure NMR spectroscopy
US6333149B1 (en) * 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US20020004489A1 (en) * 1999-08-16 2002-01-10 Yanggu Shi Retinoid receptor interacting polynucleotides, polypeptides, and antibodies
US20020006640A1 (en) * 1999-11-04 2002-01-17 Jian Ni Uteroglobin-like polynucleotides, polypeptides, and antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUKITS S.F. ET AL: "Solution Structure of the tumor necrosis factor receptor-1 death domain", J MOL BIOL, vol. 310, no. 4, 20 July 2001 (2001-07-20), pages 895 - 906, XP004480486 *
TELLIEZ J.B. ET AL: "Mutational analysis and NMR studies of the death domain of the tumor necrosis factor receptor-1", J MOL BIOL, vol. 300, July 2000 (2000-07-01), pages 1323 - 1333, XP004469106 *

Also Published As

Publication number Publication date
AU2003253589A1 (en) 2003-11-10
WO2003091700A2 (en) 2003-11-06
AU2003253589A8 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
EP2295465A3 (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
HK1200854A1 (en) Methods for antibody engineering
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
EP0930366A3 (en) Binding domains in delta proteins
MXPA04008077A (en) ANTI-Abeta ANTIBODIES AND THEIR USE.
ATE384792T1 (en) ANTIBODY VARIANTS WITH HIGHER BINDING AFFINITIES COMPARED TO PARENTAL ANTIBODIES
EP1708745A4 (en) Antibodies for oncogenic strains of hpv and methods of their use
WO2003087129A3 (en) Immunogenic peptides, and method of identifying same
EP2343318A3 (en) Antibodies binding to a C-terminal fragment of apolipoprotein E
WO2003029458A3 (en) Method for producing protein libraries and for selecting proteins from said libraries
EP2289907A3 (en) Streptococcus agalactiae antigens I + II
IL154000A (en) Method employing antibodies for diagnosing rheumatoid arthritis
WO2005010023A3 (en) Method for prediction of an epitope
DK1167389T3 (en) Antibodies to the SEMP1 protein, method of preparation thereof, and use thereof
DE60129239D1 (en) KIT AND PROCESS FOR DETERMINING PROTEIN ESM-1
WO2005019831A3 (en) Methods for reducing complexity of a sample using small epitope antibodies
WO2004092741A3 (en) Mapping discontinuous antibody or aptamer epitopes for protein structure determination and other applications
WO2003091700A3 (en) Epitope mapping using nuclear magnetic resonance
WO2003016904A3 (en) Peptide sequence tags and method of using same
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
EP1347298A3 (en) Immunoassay method, test strip for use therein, and immunoassay apparatus
EP0331514A3 (en) Assaying the duchenne muscular dystrophy protein deletion or defect
CA2419046A1 (en) Method for detecting or measuring hbv
WO2006039367A3 (en) Resonance energy transfer system and method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP